Methods for improving skin penetration of vitamin B3 compounds

A two-step skin care regimen with varying vitamin B3 concentrations enhances skin penetration and stability, addressing stability and efficacy challenges of low pH niacinamide compositions.

JP7590462B2Active Publication Date: 2024-11-26PROCTER & GAMBLE CO
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2022574094
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-06-01
Filing Date
2021-06-01
Publication Date
2024-11-26
Estimated Expiration
2041-06-01

AI Technical Summary

Technical Problem

Existing low pH niacinamide compositions face stability issues and reduced skin penetration due to ionization and complex formation, limiting formulation flexibility and efficacy.

Method used

A method involving a two-step skin care regimen where a low pH composition with a first concentration of vitamin B3 is applied, followed by a second composition with a higher concentration, enhancing skin penetration and stability.

Benefits of technology

The regimen achieves a synergistic increase in vitamin B3 flux through the skin, improving skin care composition effectiveness and flexibility, while maintaining stability and reducing irritation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590462000015
    Figure 0007590462000015
  • Figure 0007590462000016
    Figure 0007590462000016
  • Figure 0007590462000017
    Figure 0007590462000017
Patent Text Reader

Abstract

A method for improving the penetration of vitamin B3 compounds into the skin is disclosed. The method includes a skin care regimen in which at least two skin care compositions are used in sequence to treat a target area of ​​the skin where skin health or appearance benefits are desired. A first composition applied to the skin is a low pH skin care composition containing a first concentration of a vitamin B3 compound. A second skin care composition applied to the skin is a conventional skin care composition containing a higher concentration of a vitamin B3 compound than the first composition. When applied in the proper sequence, the regimen results in an unexpectedly high vitamin B3 flux to the skin.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates generally to a method for improving the penetration of vitamin B3 compounds into the skin. More specifically, the present invention relates to a skin care regimen in which a low pH skin care composition comprising a vitamin B3 compound is applied to the skin, followed by another skin care composition comprising a higher amount of vitamin B3. [Background technology]

[0002] Skin is the first line of defense against environmental insults that can damage otherwise sensitive underlying tissues and organs. For example, skin maintains a relatively water-impermeable barrier between the organism and its environment to prevent dehydration. In addition, skin plays an important role in the appearance of the human body. Generally, most people desire younger, healthier looking skin. And for some of these people, the obvious signs of skin aging, such as thin skin, wrinkles, and age spots, are undesirable reminders of the disappearance of youth.

[0003] Both intrinsic and extrinsic factors can cause the appearance and function of the skin to deteriorate. For example, as the skin naturally ages, there is typically a reduction in the cells and blood vessels that supply the skin, as well as a flattening of the dermo-epidermal junction, which leads to a thinning and general deterioration of the skin's barrier function. In addition, lifestyle choices and environmental exposures (e.g., UV rays, pollution, cigarette smoke, fumes, wind, heat, low humidity, harsh surfactants, abrasives) can lead to the premature appearance of age spots and uneven skin tone. As a result, in a youth-conscious society, treating the signs of skin aging has become a booming business. Treatments range from beauty creams and moisturizers to various forms of cosmetic surgery.

[0004] Numerous agents, both natural and synthetic, are known for use in commercially available skin care compositions to treat various skin conditions, particularly those associated with aging. One example of a well-known class of skin care agents is vitamin B3 compounds, such as niacinamide, which are used in the cosmetics industry to provide various skin health benefits. For example, U.S. Patent No. 5,833,998 discloses the use of niacinamide to regulate the oily / shiny appearance of skin, and U.S. Patent No. 5,968,528 discloses the use of niacinamide to regulate the signs of skin aging. More recent studies suggest that low pH compositions containing niacinamide may improve efficacy, as described, for example, in U.S. Patent No. 9,833,398 and U.S. Patent Application Publication No. 2020 / 0009123. However, low pH niacinamide compositions can sometimes suffer from stability issues due to their ability to ionize and complex with other ingredients in the composition. Thus, formulating niacinamide at low pH can limit formulation flexibility. Additionally, without being limited by theory, it is believed that the ionized form of niacinamide can inhibit penetration through the skin barrier, which is composed of highly keratinized corneocytes in a lipid matrix. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] U.S. Patent No. 5,833,998 [Patent Document 2] U.S. Patent No. 5,968,528 [Patent Document 3] U.S. Patent No. 9,833,398 [Patent Document 4] US Patent Application Publication No. 2020 / 0009123 Summary of the Invention [Problem to be solved by the invention]

[0006] It is therefore desirable to provide a method for improving the skin permeation of vitamin B3 compounds. It is also desirable to improve the skin permeation of stable vitamin B3 compounds from low pH compositions. [Means for solving the problem]

[0007] A method for improving skin penetration of a vitamin B3 compound, the method comprising: identifying a target area of ​​the skin where a skin health or appearance benefit is desired; applying a low pH skin care composition to the target area of ​​the skin, the low pH skin care composition comprising a first concentration of a vitamin B3 compound; and then applying a second skin care composition to the target area of ​​the skin, the second skin care composition comprising a second concentration of a vitamin B3 compound, the second concentration being greater than the first concentration. [Brief description of the drawings]

[0008] [Figure 1] 1 shows the results of a skin penetration assay. [Diagram 2] 1 shows the results of a skin penetration assay. [Diagram 3] The results of an in vitro low irritation test are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] The ability of vitamin B3 compounds to provide skin health and / or appearance benefits is well known. However, to provide the desired benefits, vitamin B3 compounds need to penetrate the skin, which is generally governed by Fick's Law of Diffusion. Fick's Law of Diffusion indicates that the flux of vitamin B3 compounds through the skin is directly proportional to the concentration difference of the vitamin B3 compounds. Fick's Law of Diffusion can be applied using the following equation: J=KD(ΔC / h), where: J is the material flux, K is the partition coefficient from the formulation, D is the diffusion coefficient into the skin, ΔC is the concentration difference, H is the throw distance (eg, the thickness of the stratum corneum). Thus, when a combination of compositions containing different concentrations of vitamin B3 compounds is applied to skin, for example, as a regimen (i.e., sequentially), the lower concentration composition effectively dilutes the higher concentration composition, which results in an overall lower flux of niacinamide through skin compared to the higher concentration composition alone.However, it has been surprisingly discovered that by first applying a low pH composition containing vitamin B3 compounds to skin, followed by a second skin care composition containing a higher concentration of niacinamide, the flux of vitamin B3 compounds through skin is much higher than expected, and in some cases, exceeds the individual flux of the higher concentration composition.This discovery is particularly unexpected, since low pH formulations promote greater ionization of vitamin B3, thus reducing its expected permeability.This synergistic increase in the flux of vitamin B3 through skin provides many potential benefits, such as, for example, formulation flexibility and improved efficacy of skin care compositions and / or regimens.

[0010] References herein to an "embodiment" or the like mean that a particular material, feature, structure, and / or characteristic described in connection with that embodiment is included in at least one embodiment, and optionally multiple embodiments, but do not mean that all embodiments incorporate the described material, feature, structure, and / or characteristic. Moreover, materials, features, structures, and / or characteristics may be combined in any suitable manner across different embodiments, and materials, features, structures, and / or characteristics may be excluded or substituted from those described. Thus, the embodiments and aspects described herein may include or be combinable with elements or components of other embodiments and / or aspects, even if not expressly illustrated in combination, unless otherwise stated or incompatibility is stated.

[0011] In all embodiments, unless otherwise stated, all percentages are by weight of the cosmetic composition. Unless otherwise stated, all ratios are by weight. All ranges are inclusive and combinable. Significant digits do not represent limitations on the amounts listed, nor do they represent limitations on the precision of the measurements. All quantities are understood to be modified by the word "about" unless otherwise stated. Unless otherwise stated, all measurements are understood to be made at ambient conditions of approximately 25°C, where "ambient conditions" means conditions of approximately 1 atmosphere pressure and approximately 50% relative humidity. All numerical ranges are inclusive of narrower ranges, and the upper and lower range limits delimited are interchangeable to create further ranges not expressly delimited.

[0012] The compositions of the present invention can comprise, consist essentially of, or consist of the essential and optional components described herein. As used herein, "consist essentially of" means that the composition or component may contain additional components, but only if the additional components do not materially alter the basic and novel characteristics of the claimed composition or method. As used in this specification and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms unless the context clearly dictates otherwise.

[0013] definition "Applying" or "application" as used in connection with a composition means applying or spreading a composition of the present invention onto a human skin surface, such as the epidermis.

[0014] "Cosmetic agent" means any substance, and also any components thereof, intended to be rubbed, poured, sprinkled, sprayed, introduced, or otherwise applied to the mammalian body or any part thereof to produce a cosmetic effect. Cosmetic agents can include substances generally recognized as safe (GRAS) by the U.S. Food and Drug Administration, food additives, and materials used in non-cosmetic consumer products, such as over-the-counter drugs.

[0015] By "effective amount" is meant the amount of compounds and compositions sufficient to induce a positive benefit to keratinous tissue over the course of a treatment period. The positive benefit may be a health, appearance, and / or feel benefit, including the benefits disclosed herein, either individually or in combination. An effective amount of a compound or composition may be demonstrated using ex vivo and / or in vitro methods.

[0016] "Improving the appearance of" means providing a measurable desired change or benefit in the appearance of skin, which can be quantified, for example, by a reduction in redness, inflammation, and / or scaling of spots.

[0017] "Low pH" means a pH below 5.0 (e.g., 1.5-4.9, 2.0-4.5, 2.5-4.0, or 3.5-4.0). Suitable methods for determining the pH of a composition are described in more detail below.

[0018] "Neutral pH" means a pH between 5.0 and 8.0.

[0019] "Skin care" refers to regulating and / or improving skin condition. Some non-limiting examples include improving the appearance and / or feel of skin by providing a smoother, more uniform appearance and / or feel, increasing the thickness of one or more layers of skin, improving the elasticity or resilience of skin, improving firmness of skin, as well as reducing the oily, shiny, and / or dull appearance of skin, improving skin hydration or moisturization, improving the appearance of fine lines and / or wrinkles, improving skin exfoliation or desquamation, plumping skin, improving skin barrier properties, improving skin tone, reducing the appearance of redness or skin blemishes, and / or improving skin brightness, luster, or clarity.

[0020] "Skin care active" means a compound or combination of compounds that, when applied to the skin, provides an acute and / or long-term benefit to the skin or a type of cell normally found in the skin. Skin care actives can regulate and / or improve the skin or cells associated therewith (e.g., improve skin elasticity, skin hydration, skin barrier function, and / or cell metabolism).

[0021] "Skin care composition" means a composition that contains skin care actives and that regulates and / or improves the condition of the skin.

[0022] "Synergy" and variations thereof mean that the effect provided by the combination of two or more compounds, materials, and / or compositions is greater than the expected effect of each of them individually. For example, a synergistic effect may be demonstrated by greater than expected skin penetration of a vitamin B3 compound from two compositions having different concentrations of the vitamin B3 compound.

[0023] As used herein, "treatment period" refers to the length of time and / or frequency that a material or composition is applied to a targeted skin surface.

[0024] "Vehicle control" means a negative control that is identical to the test composition except that it contains a particular active agent of interest (eg, does not contain a vitamin B3 compound).

[0025] Regimen The method herein involves sequentially applying at least two skin care compositions to a target portion of the skin where treatment is desired. The first skin care composition is a low pH composition that includes niacinamide, and optionally other ingredients commonly used in cosmetic skin care compositions. The low pH composition is formulated to provide skin health or appearance benefits while providing good sensory properties and the ability to be low skin irritant. The second skin care composition is applied after the low pH composition (e.g., 30 seconds to 5 minutes later). The second skin care composition includes a higher concentration of a vitamin B3 compound than the low pH composition, and optionally includes other optional ingredients commonly used in skin care compositions. The first and second compositions are described in more detail below. Although the regimen is described in the context of applying two skin care compositions in sequence, it should be understood that the method contemplates applying any number of skin care compositions in sequence after application of the low pH composition.

[0026] The method involves identifying a target area of ​​skin of a person in need of treatment or where treatment is desired (e.g., an area of ​​skin exhibiting signs of skin aging such as fine lines, wrinkles, dry skin, uneven skin tone, hyperpigmentation blemishes, etc.) and applying an effective amount of the first and second skin care compositions to the target area of ​​skin over the course of a treatment period. The effective amount of the composition may vary based on the skin benefit desired by the user, the size of the treatment area, and / or the concentration of the skin care active (e.g., vitamin B3 compound). In some cases, the effective amount may be in the range of 0.1 g to 5 g (e.g., 0.2 g to 4 g, 0.3 g to 2 g, or even 0.5 g to 1 g). The target area of ​​skin may be on the skin surface of the face, such as the forehead, perioral, chin, periorbital, nose, and / or cheeks, or on another part of the body (e.g., hands, arms, legs, back, chest). In some cases, target portions of the skin may be selected that are areas of the skin that do not currently show signs of skin aging, such as hyperpigmentation spots or uneven skin tone, but that commonly exhibit such features with age. In these cases, low pH compositions can be used to help prevent the development of such undesirable skin features.

[0027] The composition can be applied topically to the target area of ​​the skin in need of treatment, and optionally to the surrounding skin, at least once a day, twice a day, or more frequently every day during the treatment period. If applied twice a day, the first and second applications are separated by at least 1-12 hours. The composition is typically applied in the morning and / or at night before going to bed. When used according to the methods herein, the composition can improve the appearance and / or function of the skin, for example, by improving the skin's texture. The improvement of the skin's texture may be achieved, for example, by reducing the size of pores, reducing roughness, reducing the presence and / or size of wrinkles, combinations thereof, and the like.

[0028] The treatment period is ideally long enough for the low pH composition to improve the appearance and / or function of the target area of ​​the skin. The treatment period typically lasts for at least one week (e.g., about 2, 4, 8, or even 12 weeks). In some cases, the treatment period may extend for multiple months (i.e., 3-12 months). In some cases, the composition is applied at least once a day or even twice a day on the majority of days of the week (e.g., at least 4, 5, or 6 days a week) during a treatment period of at least 2, 4, 8, or 12 weeks.

[0029] The step of applying the composition herein can be performed by topical application. With respect to the application of the composition, the terms "topical", "topical" or "topically" mean that the composition is delivered to a target area (e.g., psoriasis plaque) while minimizing delivery to skin surfaces where treatment is not desired. The composition can be applied to a skin area and gently massaged. The form of the composition or dermatologically acceptable carrier should be selected to facilitate topical application. Although certain embodiments herein contemplate applying the composition locally to an area, it will be understood that the composition herein can also be applied systemically or broadly to one or more skin surfaces. In certain embodiments, the composition herein can be used as part of a multi-step cosmetic regimen, in which the composition can be applied before and / or after one or more other compositions.

[0030] low pH composition The skin care compositions herein are low pH compositions intended for topical application to human skin to improve the appearance and / or function of the skin. In some cases, the low pH compositions may be used for the cosmetic (i.e., non-therapeutic) treatment of various skin conditions, such as hyperpigmentation (e.g., age spots), uneven skin tone, pale skin, dull skin, erythema, dry skin, sebum secretion, roughness, fine lines, wrinkles, keratosis, and combinations thereof. In some cases, the low pH compositions may be particularly suitable for improving the appearance of hyperpigmentation spots, uneven skin tone, and / or pale skin.

[0031] The low pH composition comprises an effective amount of a vitamin B3 compound, a polymeric thickener that can withstand a low pH environment, a salt / acid pH buffer system (e.g., lactic acid / sodium lactate and / or glycolic acid / sodium gluconate), and optionally, a low molecular weight silicone oil. The composition may optionally comprise a silicone emulsifier and other ingredients commonly found in topical skin care compositions. Without being limited by theory, it is believed that this combination of ingredients provides an effective skin care composition that has good feel properties and is gentle on the skin.

[0032] The low pH composition herein can be made by mixing the ingredients with a dermatologically acceptable carrier using conventional methods known to those skilled in the art. The low pH composition can be provided in various product forms, such as solutions, suspensions, lotions, creams, gels, toners, sticks, sprays, aerosols, ointments, cleansing liquid washes and solid bars, pastes, foams, mousses, shaving creams, wipes, strips, patches, powered patches, hydrogels, film-forming products, facial and skin masks (with and without insoluble sheets). The form of the composition can be obtained from the specific dermatologically acceptable carrier selected. In some cases, the low pH composition herein can be in the form of an essence. An essence is a form of topical skin care composition with a relatively concentrated loading ratio, which is typically lower in viscosity than conventional cream or lotion-type skin care compositions. In some cases, an essence can be provided in the form of a low-viscosity fluid that is marketed to specifically target a particular skin condition and / or is used in the first step of a skin care regimen. The essence products herein may have an absolute viscosity of 1 centipoise (cP) to 30,000 cP (e.g., 50 cP to 10,000 cP, or 100 cP to 7,500 cP, 200 cP to 5,000 cP, or 300 cP to 2,500 cP) at 25° C. The viscosity of the low pH compositions herein may be determined according to the rheology method provided in the Methods section below.

[0033] It has been found that at least some consumers desire a skin care essence with a certain balance between transparency and opacity. If the essence is too transparent, it may look too watery, and consumers may doubt the efficacy of the product. However, if the essence is too opaque, consumers may think that the product does not provide the light and clean feeling expected from the essence. Thus, the low pH essence products herein have an opacity of 15-75 (e.g., 20-60, or 25-50) according to the opacity test described in more detail below. In some cases, it may be desirable to limit the amount of fatty alcohols and hydrocarbon oils, such as mineral oils, present in the low pH essence, since the amount of these ingredients may unnecessarily increase the opacity of the essence. Thus, it may be desirable to provide a low pH essence that is free or substantially free (e.g., less than 3%, 2%, 1%, 0.5%, or even 0%) of hydrocarbon oils. Some non-limiting examples of suitable low pH compositions are described in co-pending US patent application Ser. No. 16 / 891,491.

[0034] Vitamin B3 Compounds The compositions include a safe and effective amount of a vitamin B3 compound for regulating various skin conditions, for example, as described in U.S. Patent No. 5,939,082. The compositions herein may include 0.1% to 10% by weight (e.g., 0.5% to 5% by weight or 1% to 4% by weight) of a vitamin B3 compound, based on the weight or volume of the composition.

[0035] As used herein, a "vitamin B3 compound" has the formula:

[0036] [ka] During the ceremony, R refers to compounds, derivatives thereof, and salts of any of the above, in which R is CONH2 (i.e., niacinamide), COOH (i.e., nicotinic acid), or CH2OH (i.e., nicotinyl alcohol). Exemplary derivatives of vitamin B3 compounds include nicotinic acid esters (e.g., tocopheryl nicotinate, myristyl nicotinate), nicotinamide riboside, nicotinyl amino acid, nicotinyl alcohol ester of carboxylic acid, nicotinic acid N-oxide, and niacinamide N-oxide, including non-vasodilatory esters of nicotinic acid. In some examples, vitamin B3 compounds such as niacinamide may have improved efficacy at relatively low pH, as described, for example, in US Patent Application Publication No. 2020 / 0009123.

[0037] In some cases, it may be desirable for the ring nitrogen of the vitamin B3 compound to be "uncomplexed" (e.g., chemically unbound and / or unhindered) in the composition and / or prior to application to the target skin surface. For example, the compositions herein may be free or substantially free (i.e., less than 3%, 2%, 1%, or even less than 0.5%) of salts or complexes of the vitamin B3 compound. Exemplary approaches to minimize or prevent the formation of undesirable salts and / or complexes include removing materials that form substantially irreversible or other undesirable complexes with the vitamin B3 compound in the composition, adjusting pH, adjusting ionic strength, using surfactants, and implementing a formulation process in which the vitamin B3 compound and materials that form complexes therewith are in different phases.

[0038] Low pH buffer system When providing a low pH composition for topical application to the skin, it is important to include a buffer system that helps maintain the pH of the composition after application to the skin. On average, the pH of human skin is typically in the range of about 5.0 to 6.0. To maintain this pH, human skin has evolved a natural buffer system that resists changes in pH. Thus, when a low pH composition is applied to the skin, the skin's natural buffer system attempts to adjust the pH of the composition to match the skin's natural pH. A low pH composition may not be able to provide the desired skin care benefits without the addition of a buffer system.

[0039] The low pH buffer system herein includes an acid buffer. A variety of acids are known for use in skin care compositions. For example, alpha hydroxy acids (e.g., citric acid, glycolic acid, malic acid, and lactic acid), beta-hydroxy acids (e.g., salicylic acid and propanoic acid), and polyhydroxy acids (e.g., gluconic acid) are commonly used as exfoliants. However, some acids are stronger than others, and / or some people may be more sensitive than others to certain concentrations of acid. Both of these factors may increase the risk of skin irritation caused by low pH compositions that include acids. Some non-limiting examples of acids that may be suitable for use as acid buffers herein are lactic acid, gluconic acid, lactobionic acid, and / or maltobionic acid. Lactic acid and gluconic acid may be particularly suitable, as they tend to be relatively gentle on the skin (i.e., less likely to cause skin irritation) compared to other acids. However, lactic acid and gluconic acid are still strong enough to provide the desired low pH in the present compositions. In addition, compositions containing lactic acid and / or gluconic acid may provide skin benefits and may provide additional skin benefits, such as improving the skin's natural moisture factor and / or stimulating collagen regeneration to help improve the visible signs of skin aging. The low pH compositions herein may contain 0.5% to 5% of a suitable acid buffer. In some cases, the low pH compositions may contain 0.75% to 4%, 1% to 3%, or 1.5% to 2.5% of an acid buffer. It should be understood that the acid buffer may be added in a form that is readily converted to the desired acid. For example, glucono-delta-lactone and other gluconic acid precursors that are readily converted to gluconic acid in the present compositions are considered gluconic acid for purposes of the present invention.

[0040] The low pH buffer system herein includes a suitable salt buffer, which may depend on the acid buffer selected. For example, it may be desirable to use sodium lactate when the acid buffer is lactic acid, and / or sodium gluconate when the acid buffer is gluconic acid. Other non-limiting examples of salts that may be suitable for use herein include additional salt buffers selected from calcium lactate, potassium lactate, zinc lactate, and potassium gluconate. The salt buffer may be present in any amount suitable to provide the buffer's ability to maintain the desired low pH of the composition upon application to the skin and for at least 1 minute thereafter (e.g., 5, 10, 15, 30, 60, or even 120 minutes or more after application) to provide sufficient time for the active ingredients in the composition to penetrate the skin. In some cases, the salt buffer may be present in the low pH composition at 0.25% to 4% (e.g., 0.5% to 3%, 0.75% to 2%, or 1% to 1.75%). In some cases, the salt buffer may be present in an acid to salt weight ratio of 1:10 to 10:1. It may be desirable to use the L-enantiomer form of the acid and / or salt buffer, since this is the form that occurs naturally in the body. Sodium lactate may be particularly suitable for use as a salt buffer, since it may also act as a humectant to help moisturize the skin. Of course, it should be understood that the present composition may optionally include other pH buffers known for use in skin care compositions.

[0041] Thickener The low pH compositions herein include polymeric thickeners that can withstand low pH electrolytic environments. That is, the thickeners do not lose their ability to thicken or stabilize compositions at low pH in the presence of an acid salt buffer system. Some conventional neutralized thickeners are known to deteriorate and / or lose their ability to suitably thicken compositions at lower pH and / or in the presence of an acid salt buffer (e.g., lactic acid / sodium lactate and gluconic acid / sodium gluconate). For example, some neutralized thickeners deteriorate in low pH environments. On the other hand, fatty alcohol thickeners such as cetyl alcohol and stearyl alcohol are generally stable at low pH, but tend to impart undesirable haze or opacity to the composition when in the form of an essence, serum, etc. It has also been found that certain anionic polymeric thickeners can provide suitable resistance to low pH environments, but cannot withstand buffer systems due to the combination of acid and salt. Thus, in some cases, the low pH compositions described herein may be free or substantially free of neutralized thickeners, fatty alcohol thickeners, and anionic thickeners. The thickeners may be present at 0.0001% to 25% by weight (e.g., 0.001% to 20%, 0.01% to 10%, 0.5% to 7%, or 1% or 5%) by weight of the composition.

[0042] Other non-limiting examples of thickening or water structuring agents that may be used herein, alone or in combination, include natural or synthetic gums, polysaccharides, carboxylic acid polymers, polyacrylamide polymers, sulfonated polymers, and copolymers thereof. Further examples include modified gums, cellulose, and superabsorbent polymers. The term "superabsorbent polymer" is understood to mean a polymer that is capable of spontaneously absorbing at least 20 times its own weight in an aqueous fluid, particularly water, especially distilled water, in a dry state. Suitable polysaccharides include alkyl hydroxyalkyl cellulose ethers, such as hydroxypropyl methylcellulose stearoxy ether. This material is sold under the trade names SANGELOSE 60L and 90L by Daido Chemical Corp. Another suitable polysaccharide includes hydrophobically modified starches, such as modified potato starch. This material is sold under the trade name STRUCTURE SOLANACE by Nouryon. Alternative polymers include crosslinked polymers in which the monomers are composed at least in part of acryloyldimethyltaurate monomers, such as sodium polyacryloyldimethyltaurate, sold under the trade name ARISTOFLEX SILK by Clariant.

[0043] It has now been found that certain anionic polymer thickeners can provide the composition with suitable resistance to low pH environments, as well as the desired feel and opacity.Thus, a particularly suitable example of an anionic thickener is polyacrylate crosspolymer-6, commercially available as SEPIMAX ZEN from Seppic, France.

[0044] Viscosity reducing oil In some cases, anionic polymer thickeners may impart an undesirable sticky feel when the low pH composition is applied to the target area of ​​the skin. It has been found that the addition of certain oils (e.g., low molecular weight hydrocarbon or silicone oils) can reduce or prevent this sticky feel. Low molecular weight silicone oils may be particularly desirable because they tend to provide a smooth, soft feel that consumers prefer over hydrocarbon oils, which can sometimes feel sticky. The molecular weight of the silicone oil depends on the length of its silicone polymer chain, which is also directly proportional to the viscosity of the silicone oil. Thus, low molecular weight silicone oils suitable for use in the present low pH compositions have a kinematic viscosity of 100 cSt or less (e.g., 1 cSt to 90 cSt, 5 cSt to 50 cSt, or even 10 cSt to 30 cSt) at 25°C. Kinematic viscosity is a common way of classifying silicone oils and can be obtained from material suppliers. A particularly suitable example of a low molecular weight silicone oil is 5 cSt dimethicone fluid. As used herein, "dimethicone" means a polydimethylsiloxane compound having the formula:

[0045] [ka]

[0046] Second Skin Care Composition The second skin care composition for use in the present regimen is not particularly limited and can include a wide variety of skin care compositions that contain vitamin B3 compounds and are suitable for topical application to skin.The second skin care composition can be provided in various product forms, including but not limited to solutions, suspensions, lotions, creams, gels, toners, sticks, pencils, sprays, aerosols, ointments, cleansing liquids (rinse-off or leave-on) and solid bars, foams, powders, mousses, shaving creams, wipes, strips, patches, hydrogels, film-forming products, facial and skin masks (with and without insoluble sheets), make-up such as foundations, eyeliners, and eyeshadows, etc.The form of the composition can be obtained from the specific dermatologically acceptable carrier selected if present in the composition.

[0047] Dermatologically acceptable carrier The low pH and second skin care compositions herein may include a dermatologically acceptable carrier ("carrier"). The phrase "dermatologically acceptable carrier" means that the carrier is suitable for topical application to keratinous tissue, has good aesthetic properties, is compatible with the actives in the composition, and does not raise any undue safety or toxicity concerns. In one embodiment, the carrier is present in a concentration of from about 50% to about 99%, from about 60% to about 98%, from about 70% to about 98%, or alternatively from about 80% to about 95% by weight of the composition.

[0048] The carrier may be in a wide variety of forms. In some cases, the solubility or dispersibility of the components (e.g., extracts, sunscreen actives, additional components) may determine the form and characteristics of the carrier. Non-limiting examples include simple solutions (e.g., aqueous or anhydrous), dispersions, emulsions, and solid forms (e.g., gels, sticks, flowable solids, or amorphous materials). In some cases, the dermatologically acceptable carrier is in the form of an emulsion. An emulsion may have a continuous aqueous phase (e.g., oil-in-water or water-in-oil-in-water emulsions) or a continuous oil phase (e.g., water-in-oil or oil-in-water-in-oil emulsions). The oil phase of the present invention may include non-silicone oils such as silicone oils, hydrocarbon oils, esters, ethers, and mixtures thereof. The aqueous phase typically includes water and water-soluble components (e.g., water-soluble moisturizers, conditioning agents, antibacterial agents, humectants, and / or other skin care actives). In some cases, however, the aqueous phase may contain components other than water, including, but not limited to, water-soluble moisturizers, conditioning agents, antimicrobial agents, humectants, and / or other water-soluble skin care actives. In some cases, the non-aqueous components of the composition include humectants, such as glycerin and / or other polyols.

[0049] In some cases, the compositions herein are in the form of oil-in-water ("O / W") emulsions that provide a light, non-greasy sensory feel. Suitable O / W emulsions herein may comprise more than 50% by weight of the composition of a continuous water phase, with the remainder being a dispersed oil phase. The water phase may comprise 1% to 99% water, based on the weight of the water phase, along with any water-soluble and / or water-miscible ingredients. In these cases, the dispersed oil phase is typically present at less than 30% by weight of the composition (e.g., 1% to 20%, 2% to 15%, 3% to 12%, 4% to 10%, or even 5% to 8%) to help avoid some of the undesirable sensory effects of oil-based compositions. The oil phase may comprise one or more volatile and / or non-volatile oils (e.g., vegetable oils, silicone oils, and / or hydrocarbon oils). Some non-limiting examples of oils that may be suitable for use in the present compositions are disclosed in U.S. Pat. No. 9,446,265 and U.S. Patent Application Publication No. 2015 / 0196464.

[0050] The carrier may contain one or more dermatologically acceptable hydrophilic diluents. As used herein, "diluents" include materials in which the vitamin B3 compound can be dispersed, dissolved, or otherwise incorporated. Hydrophilic diluents include organic hydrophilic diluents such as water, lower monohydric alcohols (e.g., C1-C4), and low molecular weight glycols and polyols, including propylene glycol, polyethylene glycol (e.g., molecular weight 200-600 g / mol), polypropylene glycol (e.g., molecular weight 425-2025 g / mol), glycerol, butylene glycol, 1,2,4-butanetriol, sorbitol esters, 1,2,6-hexanetriol, ethanol, isopropanol, sorbitol esters, butanediol, ether propanol, ethoxylated ethers, propoxylated ethers, and combinations thereof.

[0051] emulsifier When the compositions herein are in the form of an emulsion (e.g., an oil-in-water emulsion), it may be desirable to include an emulsifier to stabilize the emulsion (i.e., prevent the emulsion from phase separating). The emulsifier may be present in the composition at 0.01% to 10% (e.g., 0.05% to 5%, or 0.1% to 2%). The emulsifier may be nonionic, anionic, or cationic. In some cases, the emulsifier may be a silicone emulsifier. Some non-limiting examples of emulsifiers that may be suitable for use herein are disclosed in U.S. Pat. Nos. 3,755,560, 4,421,769, and McCutcheon's Detergents and Emulsifiers, North American Edition, pages 317-324 (1986).

[0052] Some other non-limiting examples of emulsifiers that may be suitable for use herein include ethers of polyglycols and ethers of fatty alcohols, esters of polyglycols and esters of fatty acids, ethers of polyglycols and ethers of glycosylated fatty alcohols, esters of polyglycols and esters of glycosylated fatty acids, ethers of C12-30 alcohols and ethers of glycerol or polyglycerol, esters of C12-30 fatty acids and esters of glycerol or polyglycerol, ethers of oxyalkylene modified C12-30 alcohols and ethers of glycerol or polyglycerol, ethers of C1-230 fatty alcohols including sucrose or glucose, ethers of sucrose or ethers of glucose, esters of sucrose and esters of C1230 fatty acids, esters of pentaerythritol and esters of C12-30 fatty acids, esters of sorbitol and / or esters of sorbitan and C12 Examples of emulsifiers include esters of C12-30 fatty acids, ethers of sorbitol and / or ethers of sorbitan and ethers of alkoxylated sorbitan, ethers of polyglycols and ethers of cholesterol, esters of C12-30 fatty acids and esters of alkoxylated ethers of sorbitol and / or sorbitan, and combinations thereof. A particularly useful class of emulsifiers are polyethylene glycol ethers of lauryl alcohol, such as laureth-1 to laureth-50 (e.g., laureth-4). Still other examples of emulsifiers include ethers of glycerol, polyglycerol, sucrose, glucose, or sorbitol; esters of glycerol, polyglycerol, sucrose, glucose, or sorbitol; and mixtures thereof. Another particularly useful class of emulsifiers are the alkyl esters of sorbitol and sorbitol anhydrides, such as polysorbate 20, polysorbate 21, and polysorbate 40.

[0053] Silicone emulsifiers may be suitable for use herein. Linear or branched silicone emulsifiers may also be used. Particularly useful silicone emulsifiers include polyether modified silicones such as KF-6011, KF-6012, KF-6013, KF-6015, KF-6015, KF-6017, KF-6043, KF-6028 and KF-6038, and polyglycerol linear or branched siloxane emulsifiers such as KF-6100, KF-6104 and KF-6105 (all manufactured by Shin-Etsu Chemical Co., Ltd.). A particularly suitable emulsifier for use herein is PEG-11 methyl ether dimethicone, sold by Shin-Etsu Chemical Co., Ltd. as KF-6011. Surprisingly, it has been discovered that the PEG-11 methyl ether dimethicone emulsifier improves the overall feel of the low pH composition by further reducing the sticky feel of the anionic polymer thickener. The emulsifier may be present in an amount of 0.1% to 10% (e.g., 1% to 5%, or 2% to 4%).

[0054] Other Optional Ingredients The low pH and second skin care compositions may optionally include one or more additional ingredients commonly used in cosmetic compositions (e.g., colorants, skin care actives, anti-inflammatory agents, sunscreens, emulsifiers, buffers, rheology modifiers, combinations thereof, etc.), provided that the additional ingredients do not undesirably alter the skin health or appearance benefits provided by the present composition. If incorporated into the composition, the additional ingredients should be suitable for use in contact with human skin tissue without undue toxicity, incompatibility, instability, allergic response, etc. Some non-limiting examples of additional actives include vitamins, minerals, peptides and peptide derivatives, sugar amines, sunscreens, oil control agents, microparticles, flavonoid compounds, hair growth regulators, antioxidants and / or antioxidant precursors, preservatives, protease inhibitors, tyrosinase inhibitors, anti-inflammatory agents, moisturizers, exfoliants, skin lightening agents, sunless tanning agents, lubricants, anti-acne actives, anti-cellulite actives, chelating agents, anti-wrinkle actives, anti-atrophy actives, phytosterols and / or plant hormones, N-acyl amino acid compounds, antibacterial agents, and anti-fungal agents.Some non-limiting examples of skin care compositions and additional ingredients and / or skin care actives that may be suitable for use herein are described in U.S. Patent Application Publication Nos. 2002 / 0022040, 2003 / 0049212, 2004 / 0175347, 2006 / 0275237, 2007 / 0196344, 2008 / 0181956, 2008 / 0206373, 2010 / 00092408, 2008 / 0206373, 2010 / 0239510, 2010 / 01896 69, 2010 / 0272667, 2011 / 0262025, 2011 / 0097286, 2012 / 0197016, 2012 / 0128683, 2012 / 0148515, 2012 / 0156146, and 2013 / 0022557, as well as U.S. Patent Nos. 5,939,082, 5,872,112, 6,492,326, 6,696,049, 6,524,598, 5,972,359, and 6,174,533.

[0055] When present, optional ingredients may be included in an amount of 0.0001% to 50%, 0.001% to 20%, or even 0.01% to 10% (e.g., 50%, 40%, 30%, 20%, 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1%) by weight of the composition.

[0056] method Opacity Test Method This method is used to measure the opacity of a product or material. The results are reported as a percentage, the higher the percentage, the more opaque the sample. Before measuring the opacity, the test composition is ground for testing using an Ultra-turraxT25 (IKA, Germany) with an S 25 N-25 F dispersion tool (or equivalent) at 10,000 rpm for 1 minute, taking care not to introduce air into the sample. The sample is prepared by placing a sufficient amount of the composition into a suitable transmittance cell that provides a 2 mm light path (e.g., CM-A130 rectangular cell from Konica Minolta or equivalent). The opacity of the sample is measured using a suitable spectrophotometer that can provide tristimulus values ​​CIE XYZ under CIE D65 lighting conditions across the visible spectrum used in this method (e.g., CM-3600A spectrophotometer available from Konica Minolta, or equivalent). The spectrophotometer is set to provide tristimulus XYZ values ​​as defined by 1931 CIE using a 2° observer and D65 illuminant. Two sets of tristimulus values ​​are required to calculate opacity, one for a 2 mm sample cell of the product in front of a white background and one for a black background. Acceptable white backgrounds include the white portion of an opacity card (such as Opacity Card Form 2A, Leneta Company, Inc., Mahwah, NJ, USA, or equivalent), and acceptable black backgrounds are the black portion of an opacity card (such as Opacity Card Form 2A, Leneta Company, Inc., Mahwah, NJ, USA, or equivalent). Opacity is determined by calculating the Y tristimulus value using a black background divided by the Y tristimulus value using a white background, multiplied by 100%. Opacity is reported in whole number fractions.

[0057] Rheology Method This method provides a method for measuring the absolute viscosity of a composition or material using a BROOKFIELD brand viscometer (such as Model DV2T or equivalent) and a suitable spindle (such as RV4 or equivalent) according to the manufacturer's instructions. It is understood that one of ordinary skill in the art can select an appropriate spindle according to the manufacturer's recommendations. After calibrating the viscometer, immerse the spindle in a sufficient amount of test sample (e.g., a sufficient amount to immerse the spindle up to the immersion mark on the spindle shaft). Set the spindle rotation speed to 5 rpm and start the viscometer. Wait until the displayed viscosity reading stabilizes (approximately 10 to 30 seconds). After the reading stabilizes, take five readings at 10-second intervals. Calculate the viscosity as the average of the five readings. EXAMPLES

[0058] Example 1 - Formulation Table 1 provides examples of low pH skin care compositions described herein. The compositions were prepared using conventional methods for making skin care compositions. Such methods typically involve mixing the ingredients in one or more steps to a relatively homogeneous state, with or without heating, cooling, application of vacuum, etc. Typically, emulsions are prepared by first mixing the aqueous phase materials separately from the fatty phase materials, and then combining the two phases appropriately to obtain the desired continuous phase. Preferably, the compositions are prepared to optimize stability (physical stability, chemical stability, photostability) and / or delivery of the active materials. This optimization may include adjusting the pH (i.e., below 5), eliminating materials that may complex with the active agent and thereby adversely affect stability or delivery (e.g., eliminating tramp iron), using techniques to prevent complexation (e.g., using appropriate dispersants or double compartment packaging), using appropriate photostability techniques (e.g., incorporating sunscreen / sunscreen agents, using opaque packaging), etc.

[0059] The pH of the compositions tested in this example was measured with an ORION brand 525A pH meter (or equivalent) equipped with a flat surface electrode / probe (e.g., VWR Catalog 20 No. 89231-584). The pH meter probe was immersed directly into the undiluted sample of the composition.

[0060] [Table 1] 1 KSG-16 available from Shin-Etsu Chemical 2 CHRONOGEN YST available from Ashland, Inc. 3 PROGELINE available from Lucas Meyer Cosmetics 4 SEPIMAX ZEN available from Seppic 5 KF-6011 available from Shin-Etsu Chemical * Comparative Example

[0061] [Table 2] 6 ARISTOFLEX SILK available from Clariant 7 ELDEW SL 205 available from Ajinomoto OmniChem

[0062] [Table 3] 8 TEGO RENEWHA LACTO available from Evonik 9 TEGO RENEWHA MALTO available from Evonik 10 Available from Jungbunzlauer 11 PURAMEX Zn made by Corbion

[0063] Example 2 - Improved Skin Penetration of Vitamin B3 Compounds This example demonstrates the ability of the present regimen to improve the skin permeation of niacinamide. In this example, a low pH composition (Example I in Table 1) was applied to an ex vivo skin sample, followed by application of a second skin care composition. The second skin care compositions used in this test included various skin care compositions commercially available from Procter & Gamble Company. Each of the second skin care compositions included 5% niacinamide. In the first test (summarized in Table 2A below), the skin sample was analyzed to determine the amount of niacinamide that penetrated through the stratum corneum to the epidermis. In the second test (summarized in Table 2B below), the skin sample was analyzed to determine the total amount of niacinamide that penetrated into and / or through the skin sample.

[0064] Skin penetration method (Franz Cell) In vitro skin permeation of actives such as niacinamide from topically applied formulations can be determined using the Franz diffusion cell assay (Franz, TJ Percutaneous absorption. On the relevance of in vitro data. J. Invest. Dermatol. 64:190-195, 1975; Franz, et al. The use of excised human skin to assess the bioequivalence of topical products. Skin Pharmacol. Physiol. 22:276-286, 2009). The Franz diffusion cell assay is widely used in the skin care industry for evaluation of skin permeation and dermal absorption safety assessment.

[0065] Skin samples were prepared from split-thickness human cadaveric skin that had been thawed at ambient conditions, cut into appropriately sized sections, and placed in standard static Franz-type diffusion cells (0.79 cm) maintained at 37 °C. 2The skin samples are attached to the skin (surface area). Approximately 5 ml of receptor solution is placed in the bottom receptor compartment of each cell to collect any niacinamide that permeates throughout the skin sample. The receptor solution is phosphate buffered saline (PBS-pH 7.4) containing 1% polysorbate-20 and 0.02% sodium azide. The skin samples are allowed to equilibrate for 2 hours. Each treatment group typically has 6 replicates.

[0066] To prepare the test composition, an aliquot of the test composition was added containing approximately 3 μCi / 300 mg aliquot. 14 C-niacinamide. Test composition aliquots are mixed and assayed in triplicate for total radioactivity using ULTIMA GOLD brand liquid scintillation cocktail (LSC) (available from PerkinElmer, Boston) or equivalent and a suitable liquid scintillation counter (e.g., TRI-CARB 2500 TR brand liquid scintillation analyzer available from PerkinElmer).

[0067] Skin samples are topically dosed with 5 μL of the test composition using a positive displacement pipette. The product is gently spread over the surface of the skin using a glass rod (approximately 0.79 cm 2). When a regimen of more than one product is tested, there is a 3 minute interval between applications. At the end of the study (6 hours after dosing), the receptor solution is collected and the surface of each skin sample is wiped twice with Whatman filter paper soaked with PBS / Tween 20 and once with filter paper soaked with 70% / 30% ethanol / water to remove any unabsorbed (residual) product. The epidermis is separated from the dermis by peeling, and then the epidermal and dermal slices are dissolved overnight at 60°C in 0.50-1.25 mL of SOLUENE-350 (available from PerkinElmer). Niacinamide skin penetration is quantified using liquid scintillation counting as described above. Scintillation counting is performed on the epidermal sample, dermal sample, and receptor solution. The amount of epidermal skin penetration is the total amount of fluorescence measured from the epidermal sample (including the stratum corneum). Total penetration is the sum of the fluorescence measured from the epidermal sample, the dermal sample, and the receptor compartment. Skin penetration data is expressed as % and / or ug / cm of dose. 2 It can be expressed as:

[0068] The results of the skin permeation tests carried out in this example are summarized in Tables 2A and 2B and shown in Figures 1 and 2. The expected amount of niacinamide permeation was determined by applying Fick's law of diffusion to the total concentration of niacinamide applied to the target area of ​​skin. As can be seen in Tables 2A and 2B, the regimen provided an unexpected increase in the permeation of niacinamide in each case. In some cases, as shown in Figures 1 and 2, the regimen further provided additive skin permeation results, which are typically expected only from compositions with the same concentration of niacinamide and therefore the same thermodynamic potential for permeation. However, as can be seen in Table 2B for the OLAY REGENERIST CELLSCIENCE Anti-Aging Cream product, not all compositions provide an unexpected increase in the skin permeation of niacinamide, even when the present low pH composition is applied as a regimen.

[0069] [Table 4] *p<0.05 vs. penetration of the second composition only

[0070] [Table 5] * p<0.05 vs. penetration of the second composition only

[0071] Example 3 - Thermodynamic Potential This example qualitatively shows why applying skin care product according to this regimen will result in lower skin permeation results.In basic terms, the thermodynamic potential of vitamin B3 to permeate skin from skin care composition is directly proportional to the concentration of vitamin B3 compound in the composition.In other words, the thermodynamic potential of vitamin B3 compound can be expressed as the ratio of vitamin B3 concentration to product mass.In addition, when two compositions of vitamin B3 compound with different concentrations are combined on skin during regimen, there is a dilution effect, which reduces the thermodynamic potential of the combined composition relative to the composition with higher concentration.This effect is summarized in Table 3 below, which depends on the measured skin permeation of the test composition from Example 2.As shown in Table 3, the skin permeation of niacinamide applied in regimen is unexpectedly high.

[0072] [Table 6]

[0073] Example 4 - Opacity This example demonstrates the desired opacity of the low pH compositions. An opacity of 15-75 is generally desired. If the opacity is lower than 15, the composition appears quite watery and consumers may question its effectiveness. However, if the opacity is greater than 75, consumers may assume that the composition is thick, sticky, and / or does not penetrate the skin. In this example, compositions J, M, N, P, Q, R, S, and T were tested. In addition, the opacity of a conventional skin care composition (C1) was also tested. The conventional composition is Example 1 of US Patent No. 5,968,528 to Deckner, et al. The results of the test are summarized in Table 4. As can be seen in Table 4, compositions completely free of oil (i.e., compositions J and R) do not provide sufficient opacity, and compositions that are not adjusted to balance the amount of oil and thickener, skin care active, and / or buffer system may be too opaque, as demonstrated by composition C1.

[0074] [Table 7]

[0075] Example 5 - Hypoallergenic This example demonstrates the mildness of the present low pH compositions. The low pH compositions were tested in clinical trials, in vitro cell-based assays, and in vivo human studies to determine the relative irritation potential of the compositions.

[0076] Clinical Trials As part of the clinical trial described in Example 3 above, subjects were asked to complete a questionnaire assessing the level of irritation associated with the test product applied to the skin. The questionnaire asked subjects to assess the test product's "non-irritating to the skin". The questionnaire offered seven possible options: 1) strongly agree; 2) agree; 3) somewhat agree; 4) don't know; 5) somewhat disagree; 6) disagree; and 7) strongly disagree. The test compositions used in this example were Compositions G and I in Table 1 and the vehicle control in Example 3. The test results at weeks 4 and 8 are summarized in Table 5 below. The "top 3" refers to the percentage of subjects who answered "strongly agree", "agree", and "somewhat agree".

[0077] [Table 8]

[0078] At 4 weeks, 98% of subjects agreed that the composition of the present invention did not irritate skin, whereas 97% agreed that the vehicle control did not irritate skin.At 8 weeks, 100% of subjects agreed that the test composition did not irritate skin, whereas 98% agreed that the vehicle control did not irritate skin.Therefore, this test result suggests that the low pH composition of the present invention can improve the appearance of skin without irritating the skin of users.

[0079] In vitro testing The in vitro portion of this example examines the ability of the test composition to activate the well-known TRPV1 sensory receptor in commercially available HEK293 cells. TRP receptors (e.g., TRPA1, TRPV1, and TRPM8) are sensory receptors known to be involved in the transmission of thermal sensations (i.e., hot and cold) to the central nervous system. TRPV1 is also believed to be involved in the induction of skin sensory irritation, such as itching, burning, pain, tingling, stinging, and inflammation. Traditionally, certain human TRPV1 receptor-expressing cell lines have been used to evaluate the ability of a material or composition to activate TRPV1, particularly to evaluate the burning, tingling, taste, and / or pain-relieving effects of various consumer product formulations. In this example, HEK293 cells are pretreated with Fluo-4 AM, a calcium-binding dye, and treated with control and test compositions in a high-throughput manner using a FLIPR TETRA brand cell screening system (available from Molecular Devices, LLC) or equivalent. When the TRPV1 ion channel is activated, calcium ions enter the cell and bind to the Fluo-4 dye, generating a fluorescent signal, allowing quantification of the response. To reduce the effects of non-specific calcium mobilization unrelated to TRPV1 activation, the compound response is measured in the presence and absence of a specific TRPV1 inhibitor / antagonist compound. In the presence of a specific antagonist, the positive signal of compound-induced TRPV1 receptor activation is eliminated or reduced, thereby improving the accuracy of data collection due to compound-dependent TRPV1 activation.

[0080] TRPV1 assay To initiate the assay, HEK293 cells are cultured (80-90% confluent) for 4-5 days at 33°C and 5% CO2 in DMEM medium containing 10% FBS, high glucose, L-glutamine, phenol red, 100ug / ml G418, and sodium pyruvate (see, for example, Sadofsky, LR et al. Unique Responses are Observed in Transient Receptor Potential Ankyrin 1 and Vanilloid 1 (TRPA1 and TRPV1) Co-Expressing Cells. Cells 2014,3,616-626). The cells at the second passage are removed from the tissue culture vessel with PBS and the detached cells are centrifuged at low speed (800-1000 rpm) in a centrifuge for 3 minutes to form a pellet. Remove the PBS medium and resuspend the cell pellet in 4 mL of growth medium. 50 μg of Fluo-4 AM calcium dye dissolved in 25 μL of Pluronic F-127 is added, and the cells are then incubated for 1 h at room temperature with gentle shaking. The cells are washed once with 45 mL assay buffer (1x HBSS, 20 mM HEPES) by low speed centrifugation (800-1000 rpm) for 3 min, and then resuspended in 10 mL of assay buffer. Aliquot 100 μL (approximately 15 x 10 cells) into each well of a 96-well black flat-bottom plate. 4 The plate is left at room temperature for 30 minutes and then λ 2 is measured using a cell screening system (e.g., FLIPR TETRA or equivalent). ex 488nm and λ em Baseline fluorescence is recorded at 514 nm. Capsaicin (350 nM) is used as an agonist control on each plate and ionomycin (2 uM) is used as a positive control.

[0081] Test samples are prepared as 12X (10.8% loading) stocks in assay buffer (w / v) and allowed to stand at room temperature for 1 hour. All samples are then centrifuged at 14,000 rpm for 3 minutes. The aqueous phase is removed from the centrifuged samples, placed in a suitable tube, and mixed 1:1 with assay buffer to create a 6X stock. TRPV1 antagonist compositions are prepared by mixing the separated aqueous phase 1:1 with a 12X stock of capsazepine (final concentration 25 uM). The 6X samples are diluted 1:3 with assay buffer or a 6X stock of the TRPV1 antagonist capsazepine (25 uM). 20 μL of the diluted composition is added to triplicate 96-well plate wells to obtain a final dilution of 0.3% loading.

[0082] The maximum fluorescence value of each well up to the peak time of the agonist control response (typically 40-50 seconds) is recorded. The values ​​of the replicate wells are averaged and then converted to a percentage of the capsaicin agonist control response. Each test sample response is reported as the difference between the (mean test sample response)-(mean test sample response+antagonist). Responses less than zero are reported as "no response." Compositions M, N, and Q of Table 1 were tested in this example. The compositions shown in Tables 6A and 6B below were also tested. The test results are summarized in Table 6C and shown in FIG. 3, which, among other things, show that the lactic acid / sodium lactate buffer system of the compositions of the present invention exhibited significantly less TRPV1 activation than the comparative low pH composition. Specifically, the compositions of the present invention exhibited less than 10% TRPV1 activation relative to the agonist control.

[0083] [Table 9] 1 SYMDIOL 68 available from Symrise 2 PURAC HIPURE 90 available from Corbion 3 PURASAL S HQ-60 available from Corbion 4SEPIMAX ZEN available from Seppic 5 KF-6011P available from Shin-Etsu Chemical

[0084] [Table 10] 1 PURAC HIPURE 90 available from Corbion 2 PURASAL S HQ-60 available from Corbion 3 Available from Jungbunzlauer 4 SEPIMAX ZEN available from Seppic 5 KF-6011P available from Shin-Etsu Chemical

[0085] [Table 11]

[0086] In vivo testing The in vivo portion of this example shows that the composition is less irritating compared to the comparative low pH formulation using a different buffer system. This study was a single product blinded study using female subjects aged 25-54 years. Subjects were asked to apply approximately 0.5 g (i.e., one pump) of the test composition to the entire face twice daily (morning and night). The compositions tested in this study are provided in Table 6A above. After one week of use, subjects were asked if the test composition irritated the skin. The results of the in vivo study are summarized in Table 7 below. As can be seen from Table 7, the data suggests that the inventive example is less irritating to the skin compared to the two comparative examples.

[0087] [Table 12]

[0088] Examples / Combinations 1. A method for improving skin penetration of a vitamin B3 compound, comprising: Identifying a target area of ​​the skin where a skin health or appearance benefit is desired; applying a low pH skin care composition to a target area of ​​skin, the low pH skin care composition comprising a first concentration of a vitamin B3 compound; Thereafter, applying a second skin care composition to the target area of ​​the skin, the second skin care composition comprising a second concentration of a vitamin B3 compound, the second concentration being greater than the first concentration. 2. The method according to paragraph A, wherein the low pH composition has a pH of from about 2.0 to about 5.0, preferably from about 2.5 to about 4.5, and more preferably from about 3.0 to about 4.3. 3. The method of any one of the preceding paragraphs, wherein the second skin care composition has a pH of about 5.0 to about 8.0. 4. The method of any one of the preceding paragraphs, wherein the vitamin B3 compound is selected from the group consisting of niacinamide, nicotinic acid, nicotinyl alcohol, derivatives thereof, and combinations thereof. 5. The method of paragraph D, wherein the vitamin B3 compound is niacinamide. 6. The method of paragraph D, wherein the low pH composition comprises about 0.01% to about 3% by weight of the vitamin B3 compound. 7. The method of paragraph D, wherein the second skin care composition comprises about 2% to about 10% by weight of the vitamin B3 compound. 8. The method of any one of the preceding paragraphs, wherein the low pH buffer system further comprises an acid buffer selected from lactic acid, gluconic acid, lactobionic acid, and maltobionic acid, and a salt buffer selected from sodium lactate, sodium gluconate, calcium gluconate, and potassium gluconate. 9. The method of any one of the preceding paragraphs, wherein the weight percent ratio of the vitamin B3 compound in the low pH composition to the vitamin B3 compound in the second skin care composition is from about 1:10 to about 3:4, preferably from about 1:5 to about 1:2. 10. The low pH composition is a) a pH buffer system of about 0.1% to 5% containing an acid buffer and a salt buffer; b) about 0.1% to 5% of a polymeric thickener, including a low pH resistant thickener; c) about 0.1% to 10% of a viscosity reducing oil having a viscosity of 100 cSt or less at 25° C. 11. The method of paragraph J, wherein the stickiness reducing oil is a silicone oil, preferably dimethicone. 12. The method of any one of the preceding paragraphs, wherein the low pH composition further comprises about 0.01% to about 1% of a silicone emulsifier. 13. The method of any one of the preceding paragraphs, wherein at least one of the first and second skin care compositions comprises an additional skin care active selected from the group consisting of vitamins, minerals, peptides, sugar amines, sunscreens, oil control agents, flavonoid compounds, antioxidants, protease inhibitors, tyrosinase inhibitors, anti-inflammatory agents, moisturizers, exfoliants, skin lightening agents, anti-acne agents, anti-wrinkle agents, phytosterols, N-acyl amino acid compounds, antibacterial agents, antifungal agents, and combinations thereof. 14. The method of any one of the preceding paragraphs, wherein the skin care composition has an opacity of from about 15 to about 75, preferably from about 35 to about 60, according to the Opacity Test. 15. The method of any one of the preceding paragraphs, wherein the low pH composition exhibits less than about 10%, preferably less than about 5%, TRPV1 activation according to a TRPV1 assay. 16. The method of any one of the preceding paragraphs, wherein the low pH composition is a skin care essence product having a viscosity of about 1 cP to about 30,000 cP, preferably about 1,000 cP to about 15,000 cP, at 25°C. 17. The method of any one of the preceding paragraphs, wherein applying the low pH skin care composition and the second skin care composition over a treatment period does not result in skin irritation to the target area of ​​the skin.

[0089] Dimensions and values ​​disclosed herein should not be understood as being strictly limited to the exact numerical values ​​recited. Instead, unless otherwise indicated, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as "40 mm" is intended to mean "about 40 mm."

[0090] All documents cited herein, including any cross-referenced or related patents or patent applications, and any patent applications or patents to which this application claims priority or benefit, are incorporated herein by reference in their entirety, unless expressly stated to the contrary. The citation of any document shall not be deemed to be prior art to any invention disclosed or claimed herein, or to teach, suggest or disclose such invention, either alone or in combination with any other reference(s). Furthermore, to the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall govern.

[0091] While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.

Claims

1. Vitamin B 3 1. A method for improving epidermal penetration of a compound, said method comprising: Identifying a target area of ​​the skin where a skin health or appearance benefit is desired; applying a low pH skin care composition to the target area of ​​skin, the low pH skin care composition comprising a first concentration of niacinamide, 3 applying a compound comprising the compound; Thereafter, applying a second skin care composition to the target area of ​​skin, the second skin care composition comprising a second concentration of the vitamin B 3 and applying a compound having a second concentration greater than the first concentration; the low pH composition has a pH of 2.0 to 5.0; The method, wherein said low pH composition comprises from 0.01% to 3% by weight of said vitamin B 3 compound and said second skin care composition comprises from 2% to 10% by weight of said vitamin B 3 compound.

2. The method of claim 1 , wherein the second skin care composition has a pH of 5.0 to 8.

0.

3. 3. The method of claim 1 or 2, wherein the low pH composition further comprises an acid buffer selected from lactic acid, gluconic acid, lactobionic acid, and maltobionic acid, and a salt buffer selected from sodium lactate, sodium gluconate, calcium gluconate, and potassium gluconate.

4. Vitamin B in the low pH composition 3 Compound vs. Vitamin B in the Second Skin Care Composition 3 The method according to any one of claims 1 to 3, wherein the weight % ratio of the compounds is from 1:10 to 3:

4.

5. The low pH composition comprises: a. a 0.1% to 5% pH buffer system comprising an acid buffer and a salt buffer; b. 0.1% to 5% of a polymeric thickener, including a low pH resistant thickener; c. 0.1% to 10% of a stickiness reducing oil having a viscosity of 100 cSt or less at 25° C.

6. The method of claim 5 , wherein the stickiness reducing oil is a silicone oil.

7. The method of any one of claims 1 to 6, wherein the low pH composition further comprises 0.01% to 1% of a silicone emulsifier.

8. 8. The method of any one of claims 1 to 7, wherein at least one of the first and second skin care compositions comprises an additional skin care active selected from the group consisting of vitamins, minerals, peptides, sugar amines, sunscreens, oil control agents, flavonoid compounds, antioxidants, protease inhibitors, tyrosinase inhibitors, anti-inflammatory agents, moisturizers, exfoliants, skin lightening agents, anti-acne agents, anti-wrinkle agents, phytosterols, N-acyl amino acid compounds, antibacterial agents, anti-fungal agents, and combinations thereof.

9. The method of any one of claims 1 to 8, wherein the skin care composition has an opacity of from 15 to 75 according to the Opacity Test.

10. 10. The method of any one of claims 1 to 9, wherein the low pH composition exhibits less than 10% TRPV1 activation according to a TRPV1 assay.

11. The method of any one of claims 1 to 10, wherein the low pH composition is a skin care essence product having a viscosity of from 1 cP to 30,000 cP at 25°C.

12. 12. The method of any one of claims 1-11, wherein the applying of the low pH skin care composition and the second skin care composition over a treatment period does not result in skin irritation to the target area of ​​skin.

Citation Information

Patent Citations

  • Combined use of energy and topical compositions for the purpose of regulating mammalian skin conditions

    JP2009539763A

  • Concurrent Enhancement of Skin Penetration of Organic Base Active Agents and Organic Hydroxy Acid Active Agents as Their Ion-Pair Complexes

    US20060147508A1

  • Method of treating a skin condition

    US20200009123A1

  • Topical compositions for regulating the oily / shiny appearance of skin

    US5833998A

  • Skin care compositions

    US5968528A